Skip to main content

Lundbeck’s first out of three phase III studies on idalopirdine did not met primary endpoint

 

Clinical courses

H. Lundbeck A/S  announced the headline conclusions from the first clinical phase III study, STARSHINE, in the ongoing phase III programme evaluating the efficacy of the investigational drug idalopirdine for the symptomatic treatment of patients with mild to moderate Alzheimer's disease.

In the STARSHINE study, idalopirdine showed a weak efficacy profile as neither of the two dosages used in the study met the primary endpoint of a reduction in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score when added to donepezil. In addition, the secondary endpoints also did not show separation from placebo. The overall safety profile for idalopirdine showed that idalopirdine was safe and well tolerated. Further analysis of the data is ongoing.

"We are disappointed about the outcome of this study," said Dr. Anders Gersel Pedersen, EVP and Chief Scientific Officer at Lundbeck. "The phase II data were very encouraging but unfortunately, these data failed to replicate those findings". 

The two remaining studies, STARBEAM and STARBRIGHT,  in the phase III programme that currently are ongoing will continue as planned and data are expected in the first quarter of 2017.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email